Vallon Pharmaceuticals (VLON) Stock Analysis

What Vallon Pharmaceuticals does

Vallon Pharmaceuticals, Inc. is a biopharmaceutical enterprise focused on inventing and bringing to market new medicines for central nervous system disorders, with a particular emphasis on formulations designed to deter misuse. Its foremost investigational drug candidate, ADAIR, is an orally administered, abuse-resistant version of immediate-release dextroamphetamine, developed for the management of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also progressing ADMIR, which is another abuse-deterrent methylphenidate formulation targeting the treatment of ADHD. Founded in 2018, Vallon Pharmaceuticals, Inc. is headquartered in Philadelphia, Pennsylvania.

Key metrics

ETFs linked to VLON

Broad-market and Healthcare sector ETFs an investor holding Vallon Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how VLON fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Vallon Pharmaceuticals?

Vallon Pharmaceuticals trades under the ticker VLON on NASDAQ.

Which exchange is VLON listed on?

VLON is listed on NASDAQ.

What sector does Vallon Pharmaceuticals operate in?

Vallon Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze VLON in a portfolio?

PortView shows VLON's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.